PARATEK PHARMACEUTICALS

paratek-pharmaceuticals-logo

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacte... rial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

#SimilarOrganizations #People #Financial #Website #More

PARATEK PHARMACEUTICALS

Social Links:

Industry:
Biopharma Biotechnology Health Care

Founded:
1996-01-01

Address:
Boston, Massachusetts, United States

Country:
United States

Website Url:
http://www.paratekpharma.com

Total Employee:
101+

Status:
Active

Contact:
(617)807-6600

Email Addresses:
[email protected]

Total Funding:
133 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Domain Not Resolving Microsoft Exchange Online


Similar Organizations

akari-therapeutics-logo

Akari Therapeutics

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

restorbio-logo

resTORbio

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.


Current Advisors List

jeffrey-stein_image

Jeffrey Stein Director @ Paratek Pharmaceuticals
Board_member

kristine-peterson_image

Kristine Peterson Director @ Paratek Pharmaceuticals
Board_member

Current Employees Featured

michael-f-bigham_image

Michael F. Bigham
Michael F. Bigham CEO & Chairman @ Paratek Pharmaceuticals
CEO & Chairman
2014-06-01

christine-coyne_image

Christine Coyne
Christine Coyne Senior Vice President, Commercial @ Paratek Pharmaceuticals
Senior Vice President, Commercial
2020-01-01

Founder


walter-gilbert_image

Walter Gilbert

Stock Details


Company's stock symbol is NASDAQ:PRTK

Acquisitions List

Date Company Article Price
2014-10-30 Transcept Pharmaceuticals Transcept Pharmaceuticals acquired by Paratek Pharmaceuticals N/A

Investors List

biomedical-advanced-research-and-development-authority-barda_image

Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA) investment in Post-IPO Equity - Paratek Pharmaceuticals

omega-funds_image

Omega Funds

Omega Funds investment in Post-IPO Debt - Paratek Pharmaceuticals

aisling-capital_image

Aisling Capital

Aisling Capital investment in Post-IPO Debt - Paratek Pharmaceuticals

abingworth-management_image

Abingworth

Abingworth investment in Post-IPO Debt - Paratek Pharmaceuticals

the-baupost-group_image

The Baupost Group

The Baupost Group investment in Post-IPO Debt - Paratek Pharmaceuticals

aisling-capital_image

Aisling Capital

Aisling Capital investment in Post-IPO Equity - Paratek Pharmaceuticals

pacific-growth-equities_image

Pacific Growth Equities

Pacific Growth Equities investment in Post-IPO Equity - Paratek Pharmaceuticals

d-e-shaw-co_image

D. E. Shaw & Co.

D. E. Shaw & Co. investment in Post-IPO Equity - Paratek Pharmaceuticals

ibt-management-corporation_image

IBT Management Corporation

IBT Management Corporation investment in Post-IPO Equity - Paratek Pharmaceuticals

Official Site Inspections

http://www.paratekpharma.com Semrush global rank: 3.43 M Semrush visits lastest month: 4.5 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Paratek Pharmaceuticals"

About - Paratek Pharma

About Paratek. Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. We develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we …See details»

Our Leadership - Paratek Pharma

I value being able to engage in meaningful collaboration across the Paratek organization, working with people who share a common goal of providing patients with access to a life-saving product. Lindsay Moss, Associate Director, …See details»

Paratek Pharmaceuticals - LinkedIn

Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients ...See details»

Paratek Pharmaceuticals - Crunchbase Company Profile …

Contact Email [email protected] Phone Number 1 (617)807-6600 Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its …See details»

Evan Loh, M.D. - President - Paratek Pharmaceuticals | LinkedIn

President, Chief Operating Officer and Chief Medical Officer at Paratek Pharmaceuticals · OFFICAL PARATEK CORPORATE LINKEDIN PROFILE.<br><br>Evan Loh, M.D. has served …See details»

Paratek Pharmaceuticals, Inc. Company Profile | Boston, MA ...

Company Description: Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes life-saving therapies for life-threatening diseases …See details»

Paratek Pharmaceuticals, Inc. Company Information - Drugs.com

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for …See details»

Paratek - Overview, News & Similar companies | ZoomInfo.com

Aug 2, 2024 www.paratekpharma.com. Revenue $160.3 Million. Industry Pharmaceuticals Healthcare . Most Recent Scoops. Aug 2 2024. Open Position. Jun 6 2024. Open Position. …See details»

Life - Paratek Pharma

Paratek is powered by the innovation and hard work of our employees. We acknowledge these successes through Paratek PROUD, our employee recognition and service award program. Whether thanking a colleague, going …See details»

Paratek Pharmaceuticals - Craft

Sep 29, 2023 Paratek Pharmaceuticals has 4 employees across 2 locations and $160.27 m in annual revenue in FY 2022. See insights on Paratek Pharmaceuticals including office …See details»

Working at Paratek Pharmaceuticals - Zippia

Mar 14, 2024 www.paratekpharma.com. Organization Type. Public. CEO. Evan Loh M.d. Social Media. Paratek Pharmaceuticals, Inc. is a privately held biopharmaceutical company …See details»

Paratek Pharmaceuticals Announces Stockholder Approval of …

Sep 18, 2023 Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission. About Paratek Pharmaceuticals, …See details»

Paratek Pharmaceuticals, Inc. (Paratek Pharmaceuticals, Inc.) - 药物 …

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. About NUZYRA®NUZYRA® (omadacycline) is an antibiotic with both once-daily oral and intravenous …See details»

Contact - Paratek Pharma

Corporate Partnerships. Connect with our business development team by providing the information below or call us at 617-807-6600.See details»

Paratek Pharmaceuticals - Abingworth - Abingworth LLP

Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals …See details»

Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of …

Mar 14, 2022 Paratek Pharmaceuticals-- NUZYRA ® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% …See details»

Paratek Pharma | Grants & Funding

If you are interested in obtaining standard powder for routine clinical lab testing, please contact us at ‍[email protected] Contact Us If you would like to speak to a Paratek Medical …See details»

Paratek Pharmaceuticals Announces First Quarter 2023

May 9, 2023 As of March 31, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 45,026 $ 34,248 Total assets 150,828See details»

Careers - Paratek Pharma

Paratek is Powered by You. The team at Paratek is driven to build a company that makes a positive difference in patients' lives. To achieve this we seek those that make an impact …See details»

linkstock.net © 2022. All rights reserved